Intramolecular regulation of the sequence-specific mrna interferase activity of mazf fused to a maze fragment with a linker cleavable by specific proteases

Applied and Environmental Microbiology

Volumn 78, Issue 11, 2012, Pages 3794-3799

  Park, Jung Ho ^a   Yamaguchi, Yoshihiro ^a   Inouye, Masayori ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLEAVAGE SITES; DRUG DEVELOPMENT; FACTOR XA; FUNCTIONAL PROTEINS; FUSION PROTEINS; HEPATITIS C VIRUS; HIV-1 PROTEASE; HUMAN IMMUNODEFICIENCY VIRUS TYPE-1; MS2 PHAGE; N-TERMINALS; POLYPROTEINS; PROTEASE ACTIVITIES; RNA ENCODING; RNA VIRUS; THERAPEUTIC TREATMENTS; TOXIC PROTEINS; VIRAL INFECTIONS;

ESCHERICHIA COLI; PROTEINS; RNA; VIRUSES;

DISEASES;

CROSS LINKING REAGENT; DNA BINDING PROTEIN; ESCHERICHIA COLI PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HYBRID PROTEIN; MAZE PROTEIN, E COLI; MAZF PROTEIN, E COLI; MESSENGER RNA; NS3 PROTEIN, HEPATITIS C VIRUS; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RIBONUCLEASE; VIRUS PROTEIN;

COLIFORM BACTERIUM; DISEASE TREATMENT; DRUG DEVELOPMENT; ENZYME ACTIVITY; FRAGMENTATION; GENOME; HEPATITIS; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR ANALYSIS; PROTEIN; TOXIN; VIRAL DISEASE; VIRUS;

ARTICLE; CHEMISTRY; DIMERIZATION; ENZYME SPECIFICITY; ENZYMOLOGY; ESCHERICHIA COLI; EVALUATION; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; GENETICS; HEPATITIS C VIRUS; HUMAN; METABOLISM; METHODOLOGY;

CROSS-LINKING REAGENTS; DIMERIZATION; DNA-BINDING PROTEINS; ENDORIBONUCLEASES; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GENE EXPRESSION REGULATION, BACTERIAL; GENETIC ENGINEERING; HEPACIVIRUS; HIV PROTEASE; HUMANS; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SUBSTRATE SPECIFICITY; VIRAL NONSTRUCTURAL PROTEINS;

ESCHERICHIA COLI; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 84864106174     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.00364-12     Document Type: Article

References (25)

1. Brass V, et al. 2008. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc. Natl. Acad. Sci. U. S. A. 105:14545-14550.
2. Brik A, Wong CH. 2003. HIV-1 protease: mechanism and drug discovery. Org. Biomol. Chem. 1:5-14.
3. Carrere-Kremer S, et al. 2004. Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions. J. Biol. Chem. 279:41384-41392.
4. Chono H, et al. 2011. Acquisition of HIV-1 resistance in T lymphocytes using an ACA-specific E. coli mRNA interferase. Hum. Gene Ther. 22:35- 43.
5. Chono H, et al. 2011. In vivo safety and persistence of endoribonuclease gene-transduced CD4+ T cells in cynomolgus macaques for HIV-1 gene therapy model. PLoS One 6:e23585.
6. de Oliveira T, et al. 2003. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness? J. Virol. 77:9422-9430.
7. Foote BS, Spooner LM, Belliveau PP. 2011. Boceprevir: a protease in-hibitor for the treatment of chronic hepatitis C. Ann. Pharmacother. 45: 1085-1093.
8. Frankel AD, Young JA. 1998. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 67:1-25.
9. Freed EO. 1998. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251:1-15.
10. Ghosh AK, et al. 2011. Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. J. Med. Chem. 54:5890 -5901.
11. Kamada K, Hanaoka F, Burley SK. 2003. Crystal structure of the MazE/ MazF complex: molecular bases of antidote-toxin recognition. Mol. Cell 11:875- 884.
12. Kato N. 2000. Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation. Microb. Comp. Genomics 5:129 -151.
13. Katoh E, et al. 2003. A solutionNMRstudy of the binding kinetics and the internal dynamics of an HIV-1 protease-substrate complex. Protein Sci. 12:1376 -1385.
14. Kupiec JJ, Hazebrouck S, Leste-Lasserre T, Sonigo P. 1996. Conversion of thymidylate synthase into an HIV protease substrate. J. Biol. Chem. 271:18465-18470.
15. Lin C. 2006. HCV NS3-4A serine protease. In Tan S-L (ed), Hepatitis C viruses: genomes and molecular biology. Lilly Research Laboratories, Norfolk, United Kingdom.
16. McHutchison JG, Patel K. 2002. Future therapy of hepatitis C. Hepatology 36:S245-S252.
17. Nariya H, Inouye M. 2008. MazF, an mRNA interferase, mediates programmed cell death during multicellular Myxococcus development. Cell 132:55- 66.
18. Park JH, Yamaguchi Y, Inouye M. 2011. Bacillus subtilis MazF-bs (EndoA) is a UACAU-specific mRNA interferase. FEBS Lett. 585:2526 -2532.
19. Seeff LB. 2002. Natural history of chronic hepatitis C. Hepatology 36:S35- S46.
20. Shafer RW, et al. 2007. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21:215-223.
21. Shapira A, et al. 2012. Removal of hepatitis C virus-infected cells by a zymogenized bacterial toxin. PLoS One 7:e32320.
22. Shimazu T, et al. 2007. NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition. Genes Dev. 21:929 -941.
23. Yamaguchi Y, Park JH, Inouye M. 2009. MqsR, a crucial regulator for quorum sensing and biofilm formation, is a GCU-specific mRNA interferase in Escherichia coli. J. Biol. Chem. 284:28746 -28753.
24. Zhang J, Zhang Y, Inouye M. 2003. Characterization of the interactions within the mazEF addiction module of Escherichia coli. J. Biol. Chem. 278:32300 -32306.
25. Zhang Y, et al. 2003. MazF cleaves cellular mRNAs specifically at ACA to block protein synthesis in Escherichia coli. Mol. Cell 12:913-923.